Illustration: Sarah Grillo / Axios
Pfizer scrapped two clinical-stage obesity programs, including an oral GLP-1 candidate it inherited when it bought Metsera for $10 billion last year.
Why it matters: The cuts take some shine off one of biotech's splashiest recent takeovers.
